On June 20, 2023 Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, reported upcoming presentations by the Company and a collaborator at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, to be held June 24 – 27, 2023 in Chicago, Ill (Press release, Blue Earth Therapeutics, JUN 20, 2023, View Source [SID1234632810]). Presentations on investigational clinical and preclinical studies of therapeutic applications of radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) technology are being made at the conference. They include early clinical experience and a preclinical evaluation of 177Lu-rhPSMA-10.1, currently being investigated by Blue Earth Therapeutics as a potential PSMA-targeted therapeutic radiopharmaceutical candidate for the treatment of prostate cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
NOTE: Currently, therapeutic radiohybrid (rh) PSMA compounds are investigational and have not received regulatory approval. Presentations noted by "*" discuss results that are investigational and are not approved by the FDA.
Investigational 177Lu-rhPSMA-10.1
Poster presentations
NOTE: Poster presentations are available Saturday, June 24, 2023, from 6:00 – 8:00 PM CT and throughout the meeting in the Science Pavilion. Times for Meet the Author sessions are below.
Monday, June 26, 2023
Title:
*Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T – an intrapatient comparison
Presenter:
Ralph Bundschuh, MD, PhD, Nuclear Medicine, Faculty of Medicine, University Hospital Augsburg, Augsburg, Germany
Session Title:
MTA04-A12 Meet the Author: Oncology: Clinical Therapy & Diagnosis – Group A
Session Time:
11:15 – 11:45 AM CT
Area:
Science Pavilion Pod 12: Oncology Clinical Therapy & Diagnosis
Program ID:
346
Tuesday, June 27, 2023
Title:
*Enhanced therapeutic response to 177Lu-rhPSMA-10.1 in pre-clinical models of prostate cancer
Presenter:
Caroline Foxton, Ph.D., Blue Earth Therapeutics, Oxford, UK
Session Title:
MTA 06-B10 Meet the Author: Neurosciences/Oncology Basic & Translational – Group B
Area:
Science Pavilion Pod 10: Oncology Basic and Translational
Session Time:
1:00 – 1:30 PM CT
Program ID:
621
Blue Earth Therapeutics invites participants at the 2023 SNMMI Annual Meeting to learn more about its clinical program in the Medical Affairs information booth of its sister company, Blue Earth Diagnostics, at Booth 6025. For full session details and scientific presentation lists, please see the SNMMI online program here. Information about Blue Earth Diagnostics presence at SNMMI is available here.
About Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA)
Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) compounds consist of a radiohybrid ("rh") Prostate-Specific Membrane Antigen-targeted receptor ligand which attaches to and is internalized by prostate cancer cells, and they may be radiolabeled with imaging isotopes for PET imaging, or with therapeutic isotopes for therapeutic use – providing the potential for creating a true theranostic technology. Radiohybrid technology and rhPSMA originated from the Technical University of Munich, Germany. Blue Earth Diagnostics acquired exclusive, worldwide rights to rhPSMA diagnostic imaging technology from Scintomics GmbH in 2018, and therapeutic rights in 2020, and sublicensed the therapeutic application to its sister company Blue Earth Therapeutics. Blue Earth Diagnostics received U.S. Food and Drug Administration approval for its radiohybrid PET diagnostic imaging product for use in prostate cancer in 2023. rhPSMA compounds for potential therapeutic use are investigational and have not received regulatory approval.